Dr Shom Goel
Physician/scientist from the Dana-Farber Cancer Institute and Harvard Medical School Boston, USA.
Shom has spurred the development of clinical trials focussing on CDK4/6 inhibitors for HER 2 breast cancers.
Dr Goel is a physician-scientist at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He graduated from the University of Adelaide Medical School in 2002 and subsequently completed medical oncology training in Sydney. In 2009, he relocated to Boston to conduct his doctoral research in the laboratory of Rakesh K. Jain at the Massachusetts General Hospital. He was appointed as a Goldfarb-Rudkin Fellow in Breast Oncology at Dana-Farber in 2009, and has since developed a strong interest in new therapies targeting fundamental oncogenes in breast cancers. Of note, he has created a novel transgenic mouse model of HER2-positive disease that has facilitated the discovery of key mechanisms underlying resistance to HER2-blockade. His landmark discoveries in the laboratory have spurred the development of new clinical trials for patients with metastatic HER2-positive breast cancer. More recently, he has focused on the interactions between oncogenic signaling pathways and the immune microenvironment in breast cancers. Dr Goel currently sits on a number of international advisory panels, leads several clinical trials, and oversees the translational studies for two global randomized studies of CDK4/6 inhibitors in breast cancer. He is the recipient of two University Medals, the Bryan Hudson Medal (RACP), a Fulbright Scholarship, an ASCO Young Investigator Award, and a Fellowship from the American Australian Association.
Professor Andrew Shelling
Associate Dean and Head of the University of Auckland Medical Genetics Group.
Andrew has worked in one the worlds leading research laboratories in Oxford, at the Institute of Molecular Medicine, on the genetics of ovarian cancer. During his three years in Oxford, he was able to experience scientific research at the highest level, and to teach medical students at the prestigious Christ Church College, Oxford University, before returning back to Auckland to establish his own research laboratory,
Andrew has served as Deputy Head of Department of Obstetrics and Gynaecology (2001-2013), President of the New Zealand branch of the Human Genetics Society of Australasia (2002-2004), Deputy-Chairperson of the Advisory Committee for Assisted Reproductive Technologies (2006-2012), Director of the Bachelor of Medical Sciences Honours programme (2008-2016) and as Associate Editor for the Human Reproduction journal (2004-2013). Andrew is currently the Associate Dean (Research), Associate Dean (Performance Based Research Fund), on the Editorial Board for the Human Fertility journal and the Clinical Genetics journal, and is a Trustee for the Nurture Foundation for Reproductive Research.
Research areas of interest are in understanding the molecular changes that occur during the development of human disease, particularly those occurring in breast and ovarian cancer, and reproductive disorders.
Dr Anita Dunbier
University of Otago, Breast Cancer Research Partnership Researcher.
Anita has established the ER+ve breast cancer model in Dunedin which she is using to research two different immunotherapies in conjunction with anti-oestrogen therapies to see whether they can stimulate an immune response directed against the tumour.
Treatments that stimulate the immune system to attack tumours have revolutionised the treatment of some cancer types. However, these treatments have not yet been used effectively in breast cancer. More than three quarters of women with breast cancer present with the hormone-sensitive form of the disease and are subsequently treated with anti-oestrogen therapy. We have previously shown that treatment with anti-oestrogen drugs leads to infiltration of immune cells into breast tumours. We plan to investigate whether using either of two different immunotherapies in conjunction with anti-oestrogen therapies can stimulate an immune response directed against the tumour. This work will help assess whether these therapies are appropriate for treating oestrogen receptor positive tumours and, if so, whether they should be administered at the same time or separately.
Professor Adrian Harris
Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit and a NIHR Comprehensive Biomedical Research Center.
Adrian Harris, MD, DPhil is Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit. He is a Consultant Medical Oncologist at the National Health Service, Oxford Radcliffe Hospital Trust, an NIHR Comprehensive Biomedical Research Centre designated by Cancer Research as one of three Comprehensive Cancer Centres.
Professor Harris's research is on tumour angiogenesis, hypoxia and the metabolic response to hypoxia as key targets for anti-cancer therapy. He is interested in understanding the basic biology and science of disease, how this could be applied in the development of new treatments and selecting the right patients for the right therapies.
He received his Honours bachelor's degree in Medicine and Surgery in 1973 at Liverpool University but undertook an intercalated Biochemistry degree (first class honours) in 1969. He worked at Oxford University from 1975-1978, where he conducted research on mechanisms of resistance to anti-cancer drugs. He then took up a lectureship at the Royal Marsden Hospital where he developed an interest in the endocrine therapy of breast cancer with Professor Ian Smith and helped develop early aromatase inhibitors.
In 1981 he was appointed Professor of Clinical Oncology at the University of Newcastle Upon Tyne and in 1988 he was invited to Oxford to take up the foundation chair in Medical Oncology and lead the CRUK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, one of the leading basic science institutes in the United Kingdom.
Dr Anita Muthukaruppan
Anita is a Research Fellow who works with Professor Andrew Shelling in the Department of Obstetrics and Gynaecology, researching breast and gynaecological cancer.
In 2016, she was awarded the New Zealand Breast Cancer Foundation Belinda Scott Fellowship to investigate the role of transcription factor FOXA1 in breast cancer.
She graduated with a Bachelor of Science with First Class Honours in Biomedical Science from The University of Auckland in 2003. Her honours dissertation investigated the roles of forkhead transcription factors in ovarian cancer, under the supervision of Professor Andrew Shelling.
After working as a research assistant at the Kolling Institute of Medical Research, Sydney, Australia for 1.5 years, Anita undertook her PhD, “Gene Expression Analysis in Breast Cancer”, at The University of Auckland 2006 under the supervision of Professor Andrew Shelling and Professor Cristin Print. She was a recipient of The University of Auckland Doctoral Scholarship and the Cancer Society of New Zealand Training Scholarship in Cancer Research, and graduated in 2011. After being away for a couple of years on maternity leave, Anita joined Andrew Shelling’s laboratory in March 2014.
Anita’s primary research interests are breast cancer pathogenesis, and identification of biomarkers for diagnosis and prognosis, and the prediction of treatment response in patients.
She is mainly interested in oestrogen receptor alpha (ESR1) and the oestrogen signalling pathway in breast cancer. She is also interested in how three transcription factors that are important in breast cancer: ESR1, FOXA1 and GATA3, may work together and contribute to the breast cancer development.
Dr Annette Lasham
Annette is a Senior Research Fellow at the University of Auckland. She studied for her PhD at the University of Cambridge and then came to NZ after being offered a position at NZ’s first Biotechnology company, Genesis R&D. Five years ago she returned to academia to work with Professor Cristin Print at the University of Auckland to study breast cancer. In particular, Annette is working in the fast-paced field of “cancer genomics”, where her work is aimed at identifying new biomarkers and new drug targets for breast cancer.
Dr Logan Walker
Logan's primary research is focused on understanding how genetic variations in our DNA cause an increased risk of cancer for some individuals.
Identification of cancer-causing mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, has well-defined and actionable implications for disease prevention. However, routine diagnostic BRCA1 and BRCA2 gene screening is expensive and up to 90 per cent of these genetic tests do not return a positive result suggesting that the current selection criteria for genetic testing are inefficient. Furthermore, about 15 per cent of these tests identify a DNA sequence variant that is of unknown clinical significance creating a significant challenge for counselling and clinical decision making.
Logan is leading the team at the University of Otago that will aim to exploit a powerful new mRNA in situ hybridisation technology to develop an innovative method for prioritising patients for mutation screening and evaluating genomic sequencing results. This study has the potential to identify tumours from both familial and sporadic forms of breast cancer that may respond to drugs targeting altered BRCA1/2 genes and related pathways.
Professor Georgia Chenevix-Trench
Georgia graduated from the Department of Genetics at Trinity College in Ireland, was awarded her PhD from the Department of Human Genetics at the Medical College of Virginia, USA. She works at the QIMR Berghofer Medical Research Institute, where she heads a cancer genetics research laboratory working on the genetics of breast and other cancers, including showing that mutations in the ATM gene confer moderate risks for breast cancer.
Georgia, an Australian cancer researcher who investigates genetic predispositions to cancer.
Professor Chenevix-Trench received her undergraduate degree (BSc(Hons)) in 1980 from the Department of Genetics at Trinity College in Ireland and was subsequently awarded her PhD in 1985 from the Department of Human Genetics at the Medical College of Virginia, USA. and in 1986 she commenced her post-doctoral work there. In 1989 she moved to Australia where she started working as a research officer at the Queensland institute of Medical Research (QIMR). She currently works at the QIMR Berghofer Medical Research Institute, where she heads a cancer genetics research lab.
Professor Chenevix-Trench has published over 400 papers in peer reviewed journals and has been actively involved in science education and communication.
She was elected to the Australian Academy of Science in 2014, for her work on the genetics of breast, ovarian and other cancers, including showing that mutations in the ATM gene confer moderate risks for breast cancer.
Dr Reena Ramsaroop
Specialist Histocytopathologist at the Waitemata DHB. Reena is an intrinsic part of the New Zealand breast cancer specialist medical field.
Reena graduated from the University of Natal Medical School as a Fellow of the College of Pathologists (South Africa). She then practised as Consultant Pathologist/Senior Lecturer at the Natal Medical School. In 1996, Reena emigrated to New Zealand, practising at Diagnostic Medlab.
Since her arrival in New Zealand, Reena has completed her Ph.D (2000) and The Australasian College of Pathologist Fellowship. She developed her subspecialty interests in gynaecology, oncology and breast pathology with presentations and publications.
For many years Reena was the lead Pathologist for Breast Screen Limited (Auckland Central) and actively pursued research projects in women’s health. She was a member of the BreastScreen Advisory Group, an active member of the Auckland Breast Cancer Study Group and was president of the NZ Society of Cytology. Reena was appointed a Member of the New Zealand Order of Merit in the 2013 New Year Honours in recognition of her services as a histocytopathologist.
Irene a recent breast cancer patient of Hauraki, Ngati Raukawa ki te Tonga and Ngāpuhi descent, is passionate about the wellbeing of Māori communities and the care they receive whilst being treated for cancer.
Associate Professor Ian Campbell
Ian is a surgeon at Waikato Hospital who has specialised in the treatment of breast cancer since 1989.
He has been involved with more than 30 international clinical trials, leading several of these for Australia and NZ. He has co-supervised Sanjeewa Seneviratne for his PhD Thesis on breast cancer outcomes for Waikato women based on the Waikato Breast Cancer Register.
Co-investigator on numerous studies from the Breast Surgeons of Australia and NZ (Breast SurgANZ) Quality Audit. He has actively contributed to the Australia and NZ Breast Cancer Trials Group through trial work and on their Scientific Advisory Committee since 1992.
Ian has been elected NZ Director on the ANZBCTG Board from 2001-2014. He was Chair of the NZ Management of Early Breast Cancer Guidelines Group from 2007 to 2009, overseeing the development and publication of these guidelines.
Currently Chairing the NZ Breast Cancer Working Group charged with developing NZ standards of care for breast cancer. He has been the NZ representative on the Royal Australasian College of Surgeons Breast Section from 2002-2011 and a founding member of the Executive of Breast SurgANZ and their audit subcommittee.
Dr Vernon Harvey
Vernon is a Clinical Associate Professor in the Department of Oncology at the University of Auckland Medical School.
Vernon's primary interest is the management of patients with breast cancer. He is a keen supporter of clinical trials and the Principal Investigator of a large number of clinical trials in early and advanced breast cancer and drug development. He is an active member of several breast cancer co-operative trial groups, including the ANZ Breast Cancer Trials Group (ANZBCTG), the International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), the Breast Cancer International Research Group (BCIRG) and the Early Breast Cancer Trialist's Group (EBCTG).
Vernon is Chairman and Scientific Director of the Auckland Breast Cancer Study Group. He was made an Officer of the New Zealand Order of Merit (ONZM) for services to Medicine, particularly Oncology Research in the 2010 New Years Honours.
Vernon is involved in several NZ governmental committees related to cancer and is a member of the Cancer Treatment Subcommittee of PHARMAC, the government agency responsible for public funding of medicines within the NZ Health Service.
Dr Jo Perry
Liggins Institute, University of Auckland.
Dr Jo Perry is a Senior Research Fellow at the University of Auckland’s Liggins Institute. Her research interests lie in cancer cell biology and the involvement of hormones and growth factors in the progression of cancer, particularly breast cancer.
Jo completed her PhD at the Institute of Cancer Research in London and was awarded a National Health and Medical Research Council (NHMRC) Peter Doherty Postdoctoral Fellowship to work at the Murdoch Childrens Research Institute in Melbourne. In 2005 she joined the Breast Cancer Research Group at the Liggins Institute and established an independent research group there. Dr Perry is particularly interested in the role that human growth hormone plays in cancer progression. Her group investigates the mechanistic interactions of this hormone with conventional cancer therapies used clinically and is developing targeted therapies directed against the human growth hormone receptor.
Professor Parry Guilford
Otago University Breast Cancer Partnership New Zealand Researcher.
Parry's work with fatal forms of inherited cancers, has seen the development of diagnostic tools that have profound effects on saving lives.
Professor Parry Guilford is a Principal Investigator in the Cancer Genetics Laboratory, University of Otago and the Research Director of Pacific Edge Biotechnology Ltd. He completed his MSc at Otago in 1983, and his PhD at Cambridge University in 1989.
His research interests include the genetics of inherited cancers, in particular gastric cancer, and the application of gene expression analysis to the diagnosis and management of cancer.
Dr Francis Hunter
Dr Francis Hunter is a Research Fellow at the Auckland Cancer Society Research Centre, University of Auckland, and an Affiliate Investigator at the Maurice Wilkins Centre. His research focuses on employing cutting-edge genetic technologies to understanding mechanisms of drug and radiation responses in cancer, allowing treatments to become more precise and personalised. Dr Hunter has won a series of domestic and international awards for his work, which include academic and industry partnerships with collaborators in Australia, Canada, Germany and the United States. He is Executive Secretary for the New Zealand Society for Oncology and was recently the first New Zealander to be appointed to the Associate Member Council of the American Association for Cancer Research, the world’s largest such organisation.
Professor Stephen Fox
Stephen leads the Fox Laboratory in the Peter MacCallum Centre in Australia and Professorial Fellow in the Department of Pathology, The University of Melbourne. He took an Honors Degree and Medical Degree at the University of Bristol, UK (1986), before completing Pathology training in Oxford, UK after which he was awarded a Fellowship of the Royal College of Pathologists, UK, by examination, on first attempt in 1994.
Stephen was awarded DPhil in Medicine at the University of Oxford in 1996 for work in angiogenesis and human cancer. He moved to Christchurch, New Zealand in 1996 as a Specialist Anatomical Pathologist and Senior Lecturer at the University of Otago and established the de novo and angiogenesis research laboratory.
He returned to Oxford in 2001 as Clinical Reader in Pathology as part of the CRUK Chemopathology Group, while still coordinating the Christchurch laboratory. In February 2006 he moved to Melbourne, passed the Fellowship of the Royal College of Australasia by examination on first attempt and has recently been awarded a Fellowship in the Faculty of Science in the RCPA.
He has numerous positions of responsibility both within Peter Mac, state-based organisations and international organisations. He is a member of numerous relevant professional organisations; he reviews widely for numerous journals and grant review bodies, and is editor for three pathology journals. He sits on many pharmaceutical advisory boards for breast, lung and some gastrointestinal tumours.
Currently he has a laboratory which he established at Peter Mac focusing on prognostic and predictive markers together with the molecular pathology of cancer. Being a Clinical Pathologist, he focused on translating many of the new genomic tests including KRAS, BRAF, ALK and HER2 in colorectal, breast, lung and melanoma. He publishes widely in numerous high-impact journals, has a strong publication record in excess of 180 articles, citations in excess of 9000 (Scopus) and has an H-index of 45. He is recognised as an expert in breast and molecular pathology.
Professor Cristin Print
Cris is a Kiwi medical scientist who completed an MBChB at Auckland Medical School followed by asthma research in Dunedin and a PhD in Auckland under the supervision of Geoff Krissansen and Jim Watson. After a mini-postdoctoral period in Auckland he spent 4 years as a postdoctoral fellow at the Walter and Eliza Hall Institute in Melbourne studying apoptosis under supervision of Suzanne Cory and Jerry Adams, and 6 years at Cambridge University in England in the Department of Pathology working with Andrew Wyllie, and as a Fellow of St Edmund's College. He returned to work in New Zealand in September 2005, but still has PhD students and involvement in projects in the UK.
Over the last 10 years Cris has become increasingly interested in the conservative use of bioinformatics to improve our understanding of pathology. He is especially keen on work that brings bioinformatic information together with clinicopathological information and traditional cell biology/transgenic studies. He is involved in teaching, and is keen to help medical students and postgraduate students understand the value of research that translates from lab to clinic. In the past two years he has given 20 invited talks on the application of bioinformatics to medicine. Cris is a keen believer in collaboration between Universities and Pharmaceutical / Biotechnology companies, and has had successful collaborations with several companies including Pfizer Global research and a biotechnology company he co-founded in Japan named GNI Ltd. Most of the work Cris' laboratory undertakes involves collaboration with researchers from other disciplines, such as the Bioengineering Institute.
Professor Bridgette Robinson
A Medical Oncologist at Christchurch Hospital as well as the Mackenzie Chair in Cancer Medicine in the University of Otago Christchurch. She initiated and directs the Cancer Society Tissue Bank to support research, and is clinical director of the Mackenzie Cancer Research Group.
Her research interests include breast cancer, tumour stroma, effects of obesity, coagulation in cancer, familial cancer, and translational research, as well as clinical trials in cancer patients.
She chairs the Canterbury Comprehensive Cancer Centre which links clinicians, scientists, patients, NGOs and the community.
Dr Maria Pearce
Maria is a Consultant (Specialist) Radiation Oncologist and manages the radiotherapy treatment at Auckland Radiation Oncology (ARO).
Dr Pearse is also a Consultant Radiation Oncologist at Auckland City Hospital and a Senior Lecturer in Oncology at the University of Auckland Medical School.
Maria trained at Otago University in Dunedin, Auckland City Hospital and the Toronto Sunnybrook Regional Cancer Centre in Canada. In addition to her clinical roles at ARO and Auckland City Hospital, Dr Pearse is also the Chief Pathology Examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR), of which she is a Fellow. This is the examining and accrediting body for the Radiation Oncology specialty.
Dr Pearse is active in the field of cancer research and has a number of international peer-reviewed publications. She is also the recipient of a number of research grants and awards. Dr Pearse is an active member of the following research and professional associations: Medical Advisory Committee for the New Zealand Breast Cancer Foundation Auckland Breast Cancer Study Group National Breast Cancer Special Interest Group National Gastrointestinal Cancer Special Interest Group National Genitourinary Cancer Special Interest Group Medical Advisory Committee for Clinical Trials New Zealand Faculty of Radiation Oncology Genitourinary Group (FROGG) Trans-Tasman Radiation Oncology Group (TROG) Fellow of the Faculty of Radiation Oncology, Royal Australia and New Zealand College of Radiologists (RANZCR). Radiation OncologistArrayArrayArray
The Chair of Breast Cancer Aotearoa Coalition and was diagnosed with breast cancer when she was 41 years old.
Libby was a member of the Guideline Advisory Team that developed evidence-based clinical best practice guidelines for early breast cancer in New Zealand.
She provides a consumer perspective through membership of the New Zealand Breast Cancer Special Interest Group and the National Breast Cancer Tumour Stream Working Group which has developed the 'Standards of Service Provision for Breast Cancer Patients in NZ' guidelines.
Libby has actively campaigned on a range of breast cancer issues including the need for fully funded access to Herceptin and other breast cancer medicines, provision of breast reconstruction and timely access to radiation therapy, chemotherapy and surgery. Libby is a scientist based in Auckland.
She was made a Member of the New Zealand Order of Merit (MNZM) in the 2011 New Year's Honours list for services to women's health.
Fay joined Breast Cancer Aotearoa Coalition in 2015 because she sees an ongoing need to improve: outcomes for Maori and Pasifika women, access to medicines and medical devices and clinical trials for breast cancer patients in New Zealand.
Today Fay is a Board Member of Breast Cancer Cure (2009-Present) and a member of the Health Research Council Breast Cancer Research Partnership Assessment Committee (2013-Present). Fay sought appointment to the Breast Cancer Cure (formerly Breast Cancer Research Trust) Board to ensure funding for ongoing research to improve early detection, predictive and prognostic diagnosis with the discovery and development of new targeted treatments and prevention.
In 2013 Fay was diagnosed with breast cancer and her focus sharpened and become more personal.
Early in her career she was a business and change strategist with KPMG and KPMG Consulting for 20 years. She managed her own consultancy from 2005-12 and for 7 years was a Crown Owned Entity board member.
Dr Rueben Broom
A Medical Oncologist at Auckland City Hospital and Canopy Cancer Care. He is also an honorary senior clinical lecturer in oncology at the University of Auckland.
Graduated from medical school, University of Auckland in 1999 and became a Fellow of the Royal Australasian College of Physicians in 2006. Between 2006 and 2008 he completed a clinical research fellowship at Princess Margaret Hospital, Toronto, Canada, focusing on breast and renal malignancies before returning to New Zealand.
Reuben is an active researcher in both breast and renal cancers. He is an investigator on multiple phase II and III clinical trials, including leading investigator-initiated phase II trials. He is also conducting translational research in these malignancies in collaboration with several Auckland-based laboratories.
Although Reuben is very much engaged with the biology of cancer and drug development, he prides himself on clear communication with patients and empowering them with the knowledge to make the decisions that are right for each individual.
Dr Mike Baker
Mike came to New Zealand from Zimbabwe over 30 years ago. He worked at North Shore Hospital for over 20 years. Mike has been involved in all aspects of the Royal Australian and New Zealand College of Radiologists including an Australasian Councillor, Chair of the New Zealand Branch and a Senior Examiner.
He is a radiologist at TRG Imaging, Auckland Breast Centre and Breast Screen Waitemata Northland. Mike is the Clinical Managing Director of TRG Imaging.
Specialty – Breast imaging and intervention, ultrasound and quality in radiology.
Dr Richard Isaacs
Breast Cancer Aotearoa Coalition is delighted that Palmerston North oncologist, Dr Richard Isaacs has been acknowledged in the Queen’s Birthday honours as a Member of the New Zealand Order of Merit.
Dr Isaacs was instrumental in the battle to secure Government funding for a 12-month treatment programme of Herceptin for women with HER2 Positive breast cancer.
He’s been honoureBCAC chairperson, Libby Burgess, says Dr Isaacs award is well deserved.d for his contribution to ensuring cancer patients have access to world-class treatment, as well as his contributions to research and breast cancer care.
Dr Isaacs is chairman of the Breast Cancer Special Interest Group, a sub-group of the New Zealand Association of Cancer Specialists. He has been involved in more than 20 medical oncology clinical trials, is vice president of the Palmerston North Research Foundation and has worked extensively with Massey University's Institute of Molecular Biosciences, particularly with breast cancer and melanoma researcher Kathryn Stowell.
Dr Erica Whineray Kelly
Erica is an oncoplastic breast cancer surgeon and advocate based in Auckland.
Erica co-founded and is the Managing Director of both Auckland Breast Centre (ABC) and Focus Radiotherapy. ABC is a leading tertiary level breast cancer centre, and Focus Radiotherapy has introduced Intrabeam single dose intraoperative radiotherapy to NZ. As an advocate, Erica has worked closely with consumer groups to put intraoperative radiotherapy onto the government work-list for the assessment to place in the public system.
Erica is also a consultant and surgical auditor for the national breast screening programme, a member of New Zealand Global Women, Australasian and European breast cancer organisations, is a Be. Accessible Fab 50 leader as an advocate in the accessibility space, and was a founding member of the advisory board of the InZone Girls project.